Seminars in surgical oncology—Pancreas cancer adjuvant therapy trials

Yasmin Essaji, Flavio G. Rocha

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Adjuvant therapy for pancreatic cancer has undergone a paradigm shift in the last 30 years. Before the 1990s, surgery was the main treatment with high morbidity and minimal long-term survival. In the mid-1980s, GITSG showed a doubling of overall survival from 11 to 20 months with 5-fluorouracil-based chemoradiation and now the PRODIGE trial showed the benefit of FOLFIRINOX with the longest overall survival to date approaching 5 years. Further investigation on the agents, duration and sequencing of therapy remains ongoing.

Original languageEnglish (US)
Pages (from-to)1467-1474
Number of pages8
JournalJournal of surgical oncology
Issue number6
StatePublished - May 1 2021


  • adjuvant chemoradiation
  • adjuvant chemotherapy
  • evidence-based medicine
  • pancreatic cancer

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Seminars in surgical oncology—Pancreas cancer adjuvant therapy trials'. Together they form a unique fingerprint.

Cite this